A jury in state Superior Court in Atlantic City said an osteoporosis medicine made by Merck did not cause a Pennsylvania woman’s jawbone to deteriorate.
The jury announced its verdict this morning.
Alison Rosenberg, 67, of Wyncote, had alleged her eight-year use of Fosamax caused her jawbone to gradually deteriorate after a tooth extraction.
Rosenberg’s lawyers had argued that Merck, which is based in Whitehouse Station, never changed a warning label on the medicine to reflect the Food and Drug Administration’s concerns about a possible connection between oral bisphosphonates, such as Fosamax, and osteonecrosis of the jaw.
Merck’s attorneys maintained Roseberg had an extensive history of periodontal problems and sterioid use so her condition could not be spefically linked to Fosamax.
The trial began Jan. 24 before Judge Carol Higbee. The number of lawsuits blaming Merck's fosamax for osteonecrosis had reached nearly 400 as of December. The cases are being heard by Higbee as a "mass tort'' case.
Monday, February 14, 2011
Jury finds in favor of Merck in N.J. Fosamax case | NJ.com
via nj.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment